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Abstract Reverse transcription of HIV-1 vRNA into the
double-stranded DNA provirus involves initiation of plus-strand
DNA synthesis at the polypurine tract (PPT) by reverse
transcriptase (RT). The PPT is highly conserved among the
known human immunodeficiency virus (HIV-1) strains and is a
possible target for triplex formation. We show the effects of
triple-helix formation by assays of primer extension inhibition in
vitro, using a two-strand system (foldback triplex-forming
oligonucleotides (FTFOs)) targeted to the PPT of HIV-1. The
two-stranded composition of a triple-helix is thermodynamically
and kinetically superior to the three-strand system. The FTFOs
inhibited the RT activity in a sequence-specific manner, i.e. the
triplex actually formed at the PPT and blocked the RT. The
FTFOs containing the phosphorothioate groups at the antisense
sequences showed greater 3P-exonuclease resistance. In HIV-1-
infected MOLT-4 cells, the FTFOs containing the phosphor-
othioate groups at the antisense sequence sites and guanosine rich
parts within the third Hoogsteen base-pairing sequence inhibit
the replication of HIV-1 more effectively than the antisense
oligonucleotides, indicating sequence-specific inhibition of HIV-1
replication.
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1. Introduction
The human immunode¢ciency virus (HIV-1), the etiological
agent of the acquired immunode¢ciency syndrome, behaves as
a classical retrovirus with regard to many aspects of replica-
tion. Replication of HIV-1 proceeds by means of the reverse
transcriptase (RT), which catalyzes the conversion of the sin-
gle-stranded viral RNA genome into dsDNA and allows for
integration into the cellular genome [1^4]. This process in-
volves multiple steps. The RNAse H activity of the RT cata-
lyzes hydrolysis of the viral RNA from an RNA/DNA hybrid
molecule [3]. A 16 nucleotide (nt) polypurine tract (PPT),
which is resistant to RNAse H cleavage, serves as a primer
for plus-strand DNA synthesis by the DNA-directed DNA-
polymerase activity of the RT. The PPT is a highly conserved
region adjacent to the 3P-end (U3) of the viral RNA and it has
an essential function during reverse transcription [5,6]. When
the homopolymeric PPT functions as a target sequence, anti-
sense oligonucleotides as well as triple-helix-forming oligonu-
cleotides (TFOs) might be useful tools to interfere with retro-
viral replication [6^13]. During reverse transcription, TFOs
targeted against single-stranded PPT-RNA or PPT-RNA/
DNA hybrids might interfere at various points. (i) At the ¢rst
stages of the RT reaction, DNA elongation during RNA-di-
rected DNA synthesis might be arrested. (ii) Hydrolysis of the
RNA with RNAse H might be blocked at the PPT region. (iii)
The initiation of plus-strand DNA synthesis can potentially be
inhibited. (iv) The RNA-polymerase of the host cell can be
blocked during the transcription of double-stranded DNA to
mRNA. (v) The triple-helix could also block the translation of
viral mRNA.
In this paper, we describe the inhibition of the RT activities
by a two-strand system (FTFOs) targeted to the PPT region
(Fig. 1). The two-strand system comprises a Watson-Crick
and Hoogsteen base-pairing sequence on a single strand con-
nected by one hairpin loop (T) 5. These are referred to as
foldback triplex-forming oligonucleotides (FTFOs) [14^20].
The formation of the pyr/pur/pyr triple-helix, which is pH-
dependent and unstable under physiological conditions, was
avoided by the substitution of G for C in the third Hoogs-
teen base-pairing strand. The FTFOs inhibit the action of the
RT most e¡ectively and form a more stable triplex with the
PPT-RNA in vitro than the TFOs. Furthermore, the modi¢ed
FTFOs show enhanced exonuclease resistance. We also de-
scribe the anti-HIV-1 activities of the FTFOs containing
phosphorothioate groups at the antisense sequence sites and
guanosine rich parts within the third Hoogsteen base-pairing
strand.
2. Materials and methods
2.1. Oligonucleotides
The oligonucleotides were synthesized by the phosphoramidite
method using an Applied Biosystems Model 392 DNA/RNA synthe-
sizer on the 1 WM scale and with controlled pore glass supports. RNA
and DNA phosphoramidite units were purchased from PerSeptive
Biosystems. The support was treated with concentrated ammonia
for 15 h at 55‡C. The deprotected oligomers were puri¢ed by reverse
phase HPLC or by electrophoresis on 20% polyacrylamide/7 M urea
gels.
The nucleoside compositions were determined after snake venom
phosphodiesterase/bacterial alkaline phosphatase hydrolyses.
2.2. Inhibition of reverse transcription by TFOs and FTFOs
Plasmid pSV2neo JRCSF-B, containing the PPT of the HIV-1 ge-
nome, was digested by XhoI and NheI to yield a dsDNA fragment
(0.47 kb). The 23 base T7 promoter sequence was incorporated into
the dsDNA by a PCR strategy. The PCR product was transcribed
with T7 RNA-polymerase according to the manufacturer’s instruc-
tions (Ambion).
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 0 9 3 2 - 1
*Corresponding author. Fax: (81) (474) 71-8764.
E-mail: takaku@ic.it-chiba.ac.jp
FEBS 22381 23-7-99
FEBS 22381FEBS Letters 456 (1999) 186^190
2.2.1. RNA/DNA hybrid formation. In vitro transcribed RNA
containing the PPT target sequence (430 nt) (0.1 WM), a 32P-labelled
primer (5P-TCAGGGAAGTAGCCTTGTGT-3P, complementary to
HIV-1 mRNA, nt 252^271, 0.1 WM) and an antisense oligonucleotide
(5P-TCCCCCCTTTTCTTTT-3P, H-20, 1 WM) were diluted in a bu¡er
consisting of 25 mM Tris-acetate (pH 6.8), 50 mM NaCl, 10 mM
MgCl2, 1 mM K-mercaptoethanol and 0.4 mM spermine, incubated
for 5 min at 90‡C and then cooled slowly to 37‡C. For triple-helix
formation, the RNA/DNA hybrid was incubated with D1 (0.1 WM).
HIV-1 RT and dNTPs were then added to the samples. After an
incubation for 1 h at 37‡C, the samples were analyzed on a 10%
polyacrylamide-TBE-urea gel. The reactions were quanti¢ed by radio-
analytic imaging with a Bioimage analyzer, BAS 2000 (Fuji¢lm).
2.2.2. Triple-helix formation on a single-stranded RNA target. For
analyzing FTFOs, the e⁄ciency during RNA-directed cDNA synthe-
sis was performed generally as described above. FTFOs were added in
an equivalent molar to the RNA template. HIV-1 RT and dNTPs
were added and samples were incubated for 1 h at 37‡C. The samples
were analyzed on a 10% polyacrylamide-TBE-urea gel. The reactions
were quanti¢ed by radioanalytic imaging with a Bioimage analyzer,
BAS 2000 (Fuji¢lm).
2.3. Thermal denaturation pro¢les
Thermal transitions were recorded at 260 nm using a Shimadzu
UV-2200 spectrometer. The insulated cell compartment was warmed
from 15 to 90‡C, with increments of 1‡C and equilibration for 1 min
after attaining each temperature, using the temperature controller
SPR-8 (Shimadzu). Samples were heated in masked 1 cm path length
quartz cuvettes ¢tted with Te£on stoppers. Each thermal denaturation
was performed in 25 mM Tris-acetate bu¡er (pH 6.5), 0.4 mM sper-
mine, 10 mM MgCl2 and 50 mM NaCl, containing 1 WM of each
strand. The mixture of duplex and single strands was kept at 90‡C for
5 min and was then cooled to 15‡C. At temperatures below 15‡C, N2
gas was continuously passed through the sample compartment to
prevent the formation of condensation.
2.4. Cells and virus
The human T-lymphotropic virus type I (HTLV-I)-positive human
T-cell line, MT-4, and the HTLV-I non-infected T-cell line, MOLT-
4#8, were grown and maintained in RPMI 1640 medium supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
100 WU/ml penicillin and 100 Wg/ml streptomycin. A strain of HIV-
1, HTLV-IIIB, was obtained from the culture supernatant of chroni-
cally HIV-1-infected MOLT-4 cells, MOLT-4/HTLV-IIIB cells, and
was stored in a small volume at 380‡C until use. The titer of the virus
stocks was determined by 50% tissue culture infectious doses.
2.5. Anti-HIV assay
The anti-HIV activities of test compounds in a fresh HIV infection
were determined by protection against HIV-induced cytopathic e¡ects
(CPE). Brie£y, MT-4 cells were infected with HTLV-IIIB at a multi-
plicity of infection (MOI) of 0.01. HIV-infected or mock-infected MT-
4 cells (3U105 cells/ml) were placed into 96 well microtiter plates and
were incubated in the presence of various concentrations of the test
compounds. The dilutions ranged from one- to ¢ve-fold and nine
concentrations were examined. All experiments were performed in
triplicate. After 5 days of culturing at 37‡C in a CO2 incubator, the
cell viability was quanti¢ed by a colorimetric assay monitoring the
ability of viable cells to reduce 3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-
yl-tetrazolium bromide (MTT) to a blue formazan product. Absor-
bances were read in a microcomputer-controlled photometer (Titertec
Multican Labsystem Oy, Helsinki, Finland) at two wavelengths
(540 and 690 nm). The absorbance measured at 690 nm was automati-
cally subtracted from that at 540 nm, to eliminate the e¡ects of non-
speci¢c absorption. All data represent the mean values of triplicate
wells. These values were then translated into percentages per well,
cytotoxicity and anti-viral protection [21,22].
The CD4+ T-cell line, MOLT-4 (3U105 cells/ml), was infected with
HTLV-IIIB at a MOI of 0.01. After a 2 h infection, the cells were
washed and treated with the synthetic oligonucleotides at a 1 WM
concentration in the culture medium. After 2 days, the medium was
removed and fresh medium containing the oligonucleotides at a 1 WM
concentration was added. Virus replication was monitored at the cel-
lular level by syncytia formation and in the culture supernatants by a
p24 ELISA (Cellular Products). At the time points indicated, an ali-
quot of the culture supernatant was removed for p24 antigen analysis
and was replaced by fresh medium. Every 4 days, viable cells were
counted and passed at 3U105 cells/ml [23].
3. Results and discussion
3.1. Inhibition of reverse transcription by TFOs and FTFOs
The structure of the three-strand system with the TFO was
designed for applications in cell culture tests, which require
high thermodynamic stability of the triple-helix and a su⁄-
ciently long half-life of the TFOs to allow for the slow process
of triple-helix formation with the target strand before their
degradation [24,25]. These chemical modi¢cations stringently
require the physiological conditions in living cells for triple-
helix formation. Here, another approach was taken. The
FTFO recognizes the target sequence twice, unlike conven-
tional antisense and antigen oligonucleotides. The FTFO rec-
ognizes the target sequence ¢rst when it binds through Wat-
son-Crick hydrogen bonding, followed by the second
recognition in which the other half of the oligonucleotide
folds back onto the already formed duplex to form Hoogsteen
hydrogen bonds (triplex). Therefore, in principle, FTFOs are
expected to exhibit a greater sequence-speci¢city than conven-
tional antisense and antigen oligonucleotides.
In order to test direct inhibition of reverse transcription by
the FTFOs, primer extension assays were performed with a
primer binding downstream of the PPT. A RNA of 430 nu-
cleotides in length, transcribed in vitro from plasmid pSV2neo
Fig. 1. The sequences of the oligonucleotides of the three-strand
(TFOs) and two-strand (FTFOs) systems used in this work. The tar-
get PPT-RNA is indicated as bold face. The nucleotide sequences of
the RNA/DNA hybrid substrate, consisting of the HIV-1 mRNA
(430 nt) and the 20-mer antisense phosphodiester oligonucleotide (H
20) complementary to the PTT region, are shown above.
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JRCS-B and encompassing the PPT region of the HIV-1 ge-
nome, was used as the template. We determined whether the
three-strand system or the two-strand system could interfere
with the enzyme activities of the RT. Various phosphoro-
thioated FTFOs were designed (Fig. 1). The motif involves
guanosine binding, by reverse-Hoogsteen hydrogen bonding,
to the guanosine of a G-C base pair (G-G-C base triplex)
[26,27]. Several studies [28^30] that investigated DNA tri-
plexes with mixed purine-pyrimidine targets and containing
G-G-C triplexes have suggested that in some instances, the
oligonucleotides may bind in a parallel orientation. The
control primer extension reaction was performed with the
antisense oligonucleotide (5P-TCCCCCCTTTTCTTTT-3P,
H-20, 0.1 WM) corresponding to the Watson-Crick parts of
the PPT region. Primer extension inhibition was assessed with
a 5P-end-labelled primer DNA (5P-TCAGGGAAGTAG-
CCTTGTGT-3P, complementary to HIV-1 mRNA, nt 252^
271) and was analyzed by gel electrophoresis and autoradio-
graphy. Fig. 2 shows the results of the FTFOs. All of the
FTFOs (DsDloopT5-37, DsDGsloopT5-37, DsDGloopT5-
37, DsDloopT5-29 and DsDGloopT5-29) showed similar in-
hibitory e¡ects on cDNA synthesis as compared with the anti-
sense oligonucleotide (0.1 WM). The in vivo target for the
FTFOs, in the case of HIV-1 reverse transcription, is a sin-
gle-stranded RNA. Interestingly, the shorter FTFOs,
DsDloopT5-29 and DsDGloopT5-29, with the shorter Hoogs-
teen sequences, can protect against cDNA synthesis as well as
the longer FTFOs (0.1 WM). The control sequences,
DsDGsloop-ran-37 and DsDGloop-ran-37, had no detectable
inhibitory e¡ects on cDNA synthesis. These results suggest
that the two-strand system was able to induce a full conver-
sion to triple-helix formation. It is worth noting that the
FTFOs conferred sequence-speci¢c inhibition.
3.2. Foldback triplex formation with target sequence
The ability of the oligonucleotides to form triple-helices was
examined by melting temperature studies. The Tm values at
pH 6.8 of the FTFOs are listed at the bottom of Fig. 2. The
Tm values of the pur/pur/pyr triplex (DsDGloopT5-37) and
DsDloopT5-37 were 46 and 43‡C, respectively. On the other
hand, DsDGsloopT5-37, with phosphorothioates at the 3P-
and 5P-ends (39‡C), hybridized more weakly with the duplex
DNA/RNA than DsDGloopT5-37. The oligomers with phos-
phorothioate internucleotidic bonds on the third strand,
which exist as a mixture of diastereoisomers, have reduced
abilities. The pur/pur/pyr triplex (DsDGloopT5-37) formed a
more stable hybrid with the DNA/RNA duplex than the pyr/
pur/pyr triplex (DsDloopT5-37) [31,32]. The DsDGloopT5-37
binds to the target sequence by the involvement of both Wat-
son-Crick and Hoogsteen domains through foldback triplex
formation. The Tm value of the D1 three-strand system
(TFOs) was 37‡C. Furthermore, the shorter FTFOs,
DsDGloopT5-29 with guanosine rich parts at the Hoogsteen
sequence, showed higher Tm values (39‡C) than the D1 three-
strand system (TFOs). In contrast, the DsDloopT5-29 had a
lower Tm value (31‡C). For the control sequences,
DsDGsloopS-ran-37 and DsDGloop-ran-37, the Tm values
were not detectable. These results support the notion that
FTFOs are thermodynamically and kinetically superior to
TFOs.
Another problem with such an a⁄nity of oligonucleotides is
their sensitivity to degradation by nucleases present in the
Fig. 2. Inhibition of primer extension by three-strand (TFOs) and
two-strand (FTFOs) systems. Primer extension assay in the presence
of FTFOs. HIV-1 mRNA (430 nt), transcribed in vitro, was primed
with a radioactively labelled oligonucleotide primer (20-mer). The
FTFOs were added and incubated. Lanes 1^7 contain the FTFOs
as indicated, at 0.1 WM concentrations. Lane a shows a primer ex-
tension with the hybrid HIV-1 mRNA (430 nt) and a radioactively
labelled oligonucleotide primer (20-mer), which binds downstream
of the PPT. Lane b, control primer extension reactions with the
antisense oligonucleotide (H 20) at a 0.1 WM concentration. Lane c,
control primer extension reactions with the antisense oligonucleotide
(H 20) and TFO, D1, at 0.1WM concentrations. M, molecular size
markers. Tm values are listed at the bottom.
Table 1
Anti-HIV activity of FTFOs in MT-4 cells
Oligonucleotides ECa;c50 CC
b;c
50
DsDloopT5-37 0.03 WM s 10 WM
DsDGloopT5-37 0.03 WM s 10 WM
DsDGloop-ran-37 5.00 WM s 10 WM
DsDGsloopT5-37 0.03 WM s 10 WM
DsDGsloop-ran-37 5.00 WM s 10 WM
DsDloopT5-29 0.08 WM s 10 WM
DsDGloopT5-29 0.04 WM s 10 WM
DsDG-ran-loopT5-37 0.20 WM s 10 WM
S-ODN-16 0.32 WM s 10 WM
aAnti-HIV-1 activity was monitored as percentage inhibition of
HIV-1-induced cytopathogenicity in MT-4 cells. The EC50 value is
the concentration of test compound that achieves 50% inhibition of
viral antigen expression.
bCytotoxicity is expressed as the percentage of cell death of MT-4
cells cultured with test compounds. The number of viable cells was
determined by the MTT assay. The CC50 is the concentration of
test compound that exhibits 50% cell toxicity.
cData represent average values for at least three di¡erent experi-
ments.
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serum, especially 3P-exonucleases. After 24 h of incubation in
medium containing 10% FBS, the two-strand system oligonu-
cleotides (DsDloopT5-37, DsDGloopT5-37, DsDGsloopT5-
37 and DsDGloopT5-29) show the same order of stabilities
as that of the stability for antisense phosphorothioate oligo-
nucleotide (S-ODN-16) (data not shown). This stabilization
should help us to design much more e⁄cient third strand
oligonucleotides, which could be used as tools in cellular bi-
ology.
3.3. Anti-HIV-1 activity of FTFOs
In order to clarify the anti-HIV activities of the FTFOs, we
tested both acutely and chronically infected cells. Control oli-
gonucleotides were prepared for comparison, such as the
FTFOs (5P-CTGTGTTGTGTTGTTGTTTTTTsCsCsCsCs-
CsCsTsTsTsTsCsTsTs-TsT-3P, DsDG-ran-loopT5-37) con-
taining a random sequence in the third Hoogsteen base pair
strand and one with a base content identical to the FTFOs
sequences and antisense oligonucleotide (5P-TsCsCsCsCs-
CsCsTsTsTsT-3P), but in a random order (DsDGsloop-ran
37 and DsDGloop-ran-37). The FTFOs (DsDloopT5-37,
DsDGsloopT5-37, DsDGloopT5-37 and DsDGloopT5-29) in-
hibited virus replication in HIV-1-infected MT-4 cells (Table
1). These oligomers possessed EC50 values of 0.03 WM, where-
as almost no cytotoxicity was observed even at a 10 WM con-
centration of the compounds. However, the shorter FTFOs,
DsDloopT5-29 with cytidine bases at the 5P-terminal sequen-
ces, protected against HIV-1-induced CPE at EC50 values of
0.08 WM. The deletion of 8 nt (DsDloopT5-29) from the third
Hoogsteen base pair strand sequences of the FTFOs
(DsDloopT5-37) is responsible for the decreased anti-HIV-1
activity, whereas the deletion of 8 nt (DsDGloopT5-29) from
the third Hoogsteen base pair strand sequence had no in£u-
ence on the anti-HIV-1 activity. The control sequences,
DsDGsloop-ran-37 and DsDGloop-ran-37, had no e¡ect (Ta-
ble 1). On the other hand, the control oligomer with the
random sequences in the third Hoogsteen base-pairing strand,
DsDG-ran-loopT5-37, possessed EC50 values of 0.2 WM. The
anti-HIV-1 activity of DsDG-ran-loopT5-37 was 7-fold lower
than that of DsDGloopT5-37, but its potent inhibition is
achieved in the antisense manner, not without the triplex man-
ner. Furthermore, antisense oligonucleotide S-ODN-16 inhib-
ited HIV-1-induced CPE at EC50 values of 0.32 WM, a sub-
stantially lower inhibitory e¡ect than that observed for its
FTFOs, DsDGloopT5-37. FTFOs recognize the target se-
quence twice, unlike conventional antisense and antigen oli-
gonucleotides. These results suggest that the FTFOs inhibited
HIV-1-induced CPE, but the random FTFOs failed to inhibit
HIV-1 replication in acutely infected MT-4 cells. Phosphoro-
thioate oligonucleotides have been shown to block the prolif-
eration of HIV-1 in acutely infected cells in a non-sequence-
speci¢c manner [33], probably by the inhibition of RT [34,35]
and/or the viral entry process [36,37]. However, the FTFOs
inhibited HIV-1-induced CPE in acutely infected MT-4 cells
in a sequence-speci¢c manner. It is noteworthy that the
FTFOs inhibit the replication of HIV-1 more e¡ectively
than the antisense phosphorothioate oligonucleotides.
Next, we examined the long-term e¡ects of FTFOs treat-
ment in HIV-1-infected MOLT-4 cells. The MOLT-4 cells
were incubated with HIV-1IIIÿB for 2 h to allow absorption.
The cells were then washed to remove the virus from the
medium and the modi¢ed FTFOs were added with fresh me-
dium. After 2 days, new medium supplemented with the oli-
gonucleotides was added. The virus production in the culture
supernatant was monitored by the HIV-1 p24 antigen assay
(Fig. 3). In this assay system, the phosphorothioate-modi¢ed
oligonucleotides cannot interfere with retroviral binding at the
CD4 receptor, because the cells were incubated with an infec-
tious HIV-1 supernatant for 2 h before the application of the
oligonucleotides. The control-infected cells (no oligomer
added) exhibited maximal HIV-1 replication at 14 days. How-
ever, in the cells treated with the DsDGloopT5-37 (1 WM),
p24 expression was inhibited by 100%, as compared to the
untreated control at 30 days. In contrast, the DsDloopT5-
37-treated cells, containing cytidine rich parts within the
third Hoogsteen base-pairing strand, expressed high levels of
p24 products after 26 days. On the other hand, the
DsDGsloopT5-37 with phosphorothioate groups at the 3P-
and 5P-ends inhibited HIV-1 replication by 64%, as compared
to the untreated control at 18 days. The oligonucleotide with
phosphorothioate groups in the third Hoogsteen base-pairing
strand has less ability to form a triple-helix. After 14 days, the
random oligomer (DsDGsloop-ran-37 and DsDGloop-ran-37)
and antisense oligonucleotide-treated cells (S-ODN-16) ex-
pressed high levels of p24. Interestingly, the short FTFOs,
DsDGloopT5-29, inhibited virus replication by 100%, as com-
pared to the untreated control at 18 days, but the treated cells
expressed high levels of p24 products after 26 days. The
DsDloopT5-29 had no detectable inhibitory e¡ect. These re-
sults suggest that the thermodynamically extractable Hoogs-
teen base-pairing structure is apparently the best structure for
the inhibitory e⁄ciency. The greatest inhibitory e¡ects on
Fig. 3. Anti-viral activity of the FTFOs and antisense oligonucleo-
tide at 1 WM. After 2 h, the virus was removed from MOLT-4 cells
newly infected with HIV-1IIIÿB and the cells were treated with the
synthetic oligonucleotides. The second treatment was performed 2
days later. Supernatants were collected and p24 expression was de-
termined by the p24 antigen assay.
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HIV-1 replication were detected with the DsDGloopT5-37 at
the 1 WM concentration.
In conclusion, the two-stranded composition of a triple-he-
lix is thermodynamically and kinetically superior to the three-
strand system. The FTFOs containing the phosphorothioate
groups at the antisense sequences showed greater 3P-exonu-
clease resistance. In HIV-1-infected MOLT-4 cells, the FTFOs
containing the phosphorothioate groups at the antisense se-
quence sites and guanosine rich parts within the third Hoogs-
teen base-pairing strand inhibit the replication of HIV-1 more
e¡ectively than the antisense oligonucleotides, indicating se-
quence-speci¢c inhibition of HIV-1 replication. In particular,
the phosphorothioated FTFOs may be useful in nucleic acid-
based anti-viral therapies with triple-helix approaches in vitro
or in vivo.
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